Cancer is when abnormal cells divide in an uncontrolled way
There are more than 200 different types of cancer.
According to estimates from the International Agency for Research on Cancer (IARC), in 2012 there were 14.1 million new cancer cases and 8.2 million cancer deaths worldwide. By 2030, the global burden is expected to grow to 21.7 million new cancer cases and 13 million cancer deaths simply due to the growth and aging of the population. The future burden will probably be even larger because of the adoption of western lifestyles, such as smoking, poor diet, physical inactivity, and fewer childbirths, in economically developing countries.
ImmuPharma has a novel concept in the potential treatment of cancer which has been developed in partnership with our collaboration partner, CNRS. It relies on the modulating effect of the Nucants on angiogenesis, the mechanism which controls the formation of micro vessels. Generally, the tumour generated micro vessels are of poor quality and offer a poor supply of blood and oxygen to the tumour. As a consequence, it makes the tumour much more resistant to cytotoxic drugs. By modulating the tumour micro vessels Nucants ameliorate the blood flow, allow a better oxygen supply and increase the intra-tumoural cytotoxic drug concentration.
About threefold increase of cytotoxic drug concentration and threefold decrease in tumour size have been observed in preclinical studies. The intended potential treatment scheme is to pre-treat the patient with Nucant and then deliver the standard dose of cytotoxic drug, Gemcitabin for example in pancreatic cancer.
To see announcement click here
The effect on blood supply delivered by Nucants is also thought to have other potential applications. Degenerative diseases of the eye (DMLA, diabetic retinopathy) are characterised by changes to blood supply. In pre-clinical studies and models, Nucants have been demonstrated to correct these pathologies.